News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Joins NHIA Future of Infusion Advisory Council
For Melinta, membership in the FIAC provides the opportunity for critical collaboration with the association and other organizations serving patients requiring infusion therapies. This work helps to enhance continuity of care as patients transition out of the hospital.
Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022
October 18, 2022 Press Release PARSIPPANY, N.J.--Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced
Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.
July 27, 2022 Press Release Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S. MORRISTOWN, N.J., July 27, 2022 — Melinta Therapeutics,
Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics
April 6, 2022 Press Release Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics MORRISTOWN, N.J., Apr. 6, 2022 — Melinta Therapeutics, LLC